Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$4.8 million.

  • Keros Therapeutics' Change in Accured Expenses fell 155.08% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year decrease of 169.74%. This contributed to the annual value of $3.0 million for FY2024, which is 43.85% down from last year.
  • Per Keros Therapeutics' latest filing, its Change in Accured Expenses stood at -$4.8 million for Q3 2025, which was down 279.32% from $2.7 million recorded in Q2 2025.
  • Keros Therapeutics' Change in Accured Expenses' 5-year high stood at $8.7 million during Q3 2024, with a 5-year trough of -$5.4 million in Q1 2024.
  • In the last 3 years, Keros Therapeutics' Change in Accured Expenses had a median value of $274,000 in 2023 and averaged $228,000.
  • As far as peak fluctuations go, Keros Therapeutics' Change in Accured Expenses soared by 4,494.85% in 2022, and later slumped by 647.65% in 2023.
  • Keros Therapeutics' Change in Accured Expenses (Quarterly) stood at -$97,000 in 2021, then soared by 4,494.85% to $4.3 million in 2022, then soared by 35.75% to $5.8 million in 2023, then plummeted by 122.45% to -$1.3 million in 2024, then slumped by 155.08% to -$4.8 million in 2025.
  • Its last three reported values are -$4.8 million in Q3 2025, $2.7 million for Q2 2025, and -$3.6 million during Q1 2025.